Journal of Pharmacology and Pharmacotherapeutics

CASE REPORT
Year
: 2019  |  Volume : 10  |  Issue : 1  |  Page : 42--44

Subconjunctival bevacizumab for recurrent conjunctival pyogenic granuloma


Nirupama Kasturi1, Tharini Senthamizh1, Hanuman Srinivas Bheemanathi2, K Ramesh Babu1 
1 Department of Ophthalmology, Jawaharlal Postgraduate Medical Education and Research, Puducherry, India
2 Department of Pathology, Jawaharlal Postgraduate Medical Education and Research, Puducherry, India

Correspondence Address:
Nirupama Kasturi
Department of Ophthalmology, Jawaharlal Postgraduate Medical Education and Research, Puducherry - 605 006
India

A 45-year-old male presented with a pyogenic granuloma of the bulbar conjunctiva of the left eye following a stick injury. It was a benign friable, hyperplastic, vascular lesion comprised of inflammatory cells and lobular capillary proliferation. The differential diagnosis includes squamous papillomas, hemangiomas, suture granulomas, and ocular surface tumors, such as squamous cell carcinoma and amelanotic melanoma. Conventional treatment includes topical corticosteroids and surgical excision. Treatment of recurrent lesions with cryotherapy, electrocautery, topical antimetabolites, and plaque irradiation has been described. We present a case of recurrent pyogenic granuloma successfully treated with two subconjunctival bevacizumab injections. The patient developed three recurrences after excision at a peripheral hospital after which he was successfully treated with excision and adjuvant subconjunctival bevacizumab 2.5 mg/0.1 ml injection. This case highlights the novel use of bevacizumab for recurrent pyogenic granuloma.


How to cite this article:
Kasturi N, Senthamizh T, Bheemanathi HS, Babu K R. Subconjunctival bevacizumab for recurrent conjunctival pyogenic granuloma.J Pharmacol Pharmacother 2019;10:42-44


How to cite this URL:
Kasturi N, Senthamizh T, Bheemanathi HS, Babu K R. Subconjunctival bevacizumab for recurrent conjunctival pyogenic granuloma. J Pharmacol Pharmacother [serial online] 2019 [cited 2020 Oct 20 ];10:42-44
Available from: http://www.jpharmacol.com/article.asp?issn=0976-500X;year=2019;volume=10;issue=1;spage=42;epage=44;aulast=Kasturi;type=0